Prosecution Insights
Prosecution Insights
182 pending office actions • 73 clients • 161 examiners • 65 art units • 0 of 182 (0%) have an AI response strategy ready • 159 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 81 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 81 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 15 (8%) |
| §103 only | 40 (22%) |
| §102 only | 3 (2%) |
| §112 only | 20 (11%) |
| Double-patenting only | 7 (4%) |
| Double-patenting + other | 18 (10%) |
| Multi-statute (no §101) | 77 (42%) |
| No statute on record | 2 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 3 | 60.6% | +50.7% |
| MIDDLETON, DANAYA L | 2 | 46.1% | +54.1% |
| KNIGHT, TERESA E | 2 | 65.7% | +48.7% |
| SPENCE, JENNIFER SUZANNE | 2 | 66.1% | +50.7% |
| PARKIN, JEFFREY S | 2 | 63.7% | +21.2% |
| MCLEOD, AFRICA MHAIRIE | 2 | 50.0% | +73.0% |
| BOECKELMAN, JACOB A | 2 | 36.1% | +46.1% |
| SALMON, KATHERINE D | 2 | 42.6% | +38.0% |
| CHONG, KIMBERLY | 2 | 72.4% | +12.7% |
| CRAIGO, WILLIAM A | 2 | 49.2% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18332603 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | MOU, LIYUAN | 157d overdue |
| 17916998 | DECELLULARIZED MENISCAL CARTILAGE AND USES THEROF | MITCHELL, EDWIN COLEMAN | 111d overdue |
| 17276032 | COMBINATION CANCER THERAPIES | ELENISTE, PIERRE PAUL | 74d overdue |
| 18005562 | ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD) | QIAN, CELINE X | 51d overdue |
| 18514277 | STORAGE SOLUTIONS FOR MAINTAINING OF AXONAL VIABILITY | BOECKELMAN, JACOB A | 49d overdue |
| 17782314 | A BIOMARKER AND USES THEREFOR | KAPUSHOC, STEPHEN THOMAS | 32d overdue |
| 17815711 | GENOME ENGINEERING THE HUMAN IMMUNOGLOBULIN LOCUS TO EXPRESS RECOMBINANT BINDING DOMAIN MOLECULES | KONOPKA, CATHERINE ANNE | 31d overdue |
| 18427737 | EBOLAVIRUS AND MARBURGVIRUS VACCINES | PARKIN, JEFFREY S | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | SALMON, KATHERINE D | 161d overdue |
| 16098145 | IMPROVED DRUG FORMULATIONS | CRAIGO, WILLIAM A | 98d overdue |
| 18514277 | STORAGE SOLUTIONS FOR MAINTAINING OF AXONAL VIABILITY | BOECKELMAN, JACOB A | 49d overdue |
| 18660178 | METHODS FOR THE LONG-TERM EXPANSION OF GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | WESTON, ALYSSA G | 46d overdue |
| 18427737 | EBOLAVIRUS AND MARBURGVIRUS VACCINES | PARKIN, JEFFREY S | 30d overdue |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | SALMON, KATHERINE D | 28d overdue |
| 17265302 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS | MCLEOD, AFRICA MHAIRIE | 8d overdue |
| 19461491 | Untitled | MIDDLETON, DANAYA L | — |
| Art Unit | Apps |
|---|---|
| 1631 | 8 |
| 1612 | 7 |
| 1682 | 7 |
| 1635 | 7 |
| 1643 | 6 |
| 1615 | 5 |
| 1683 | 5 |
| 1681 | 5 |
| 1633 | 4 |
| 1671 | 4 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19461491 | Untitled | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MIDDLETON, DANAYA L | §103§112 | Non-Final OA | — | Pending | ||
| 19363455 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | Curevac Manufacturing GmbH | BAKSHI, PANCHAM | 1623 | §103 | Non-Final OA | — | Pending | Oct 20, 2025 |
| 19096640 | METHODS, SYSTEMS AND CONTROLLERS FOR FACILITATING CLEANING OF AN IMAGING ELEMENT OF AN IMAGING DEVICE | Clearcam Inc. | LE, PETER D | 2488 | DP | Non-Final OA | — | Pending | Mar 31, 2025 |
| 19042229 | DEVICES, SYSTEMS AND METHODS FOR CLEANING OF ELONGATED INSTRUMENT SURFACE | Ascension Texas | HENDERSON, RYAN N | §102§112Other | Non-Final OA | — | Pending | Jan 31, 2025 | |
| 18872393 | APPARATUS AND METHODS FOR RAPID HEATING AND COOLING OF LIQUIDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | WEILAND, HANS R. | §102§103§112 | Non-Final OA | — | Pending | Dec 06, 2024 | |
| 18856686 | DELIVERY SYSTEM TO TARGET GRAM-NEGATIVE BACTERIA | The Wistar Institute | SHIAO, REI TSANG | §112 | Non-Final OA | — | Pending | Oct 14, 2024 | |
| 18906245 | ULTRASOUND-RESPONSIVE NANOSCALE DELIVERY PLATFORM FOR USE IN THE TREATMENT OF BIOFILM-ASSOCIATED DISEASES | Aurapeutics Ltd. | MERCIER, MELISSA S | §102§112 | Non-Final OA | — | Pending | Oct 04, 2024 | |
| 18854288 | HUMAN IGE MONOCLONAL ANTIBODIES TO PARASITIC WORM ANTIGENS AND USES THEREFOR | VANDERBILT UNIVERSITY | HAMA, JOANNE | 1645 | §101§102§103 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18836712 | LEAF-BRANCH COMPOST CUTINASE MUTANTS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LANKFORD JR, LEON B | — | Non-Final OA | — | Pending | Aug 07, 2024 | |
| 18789888 | BIOCHEMICAL AND BIOMECHANICAL CONDITIONING FOR ENHANCING PERSONALIZED MESENCHYMAL STEM CELL THERAPIES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KNIGHT, TERESA E | DP | Non-Final OA | — | Pending | Jul 31, 2024 | |
| 18763115 | APPARATUS AND METHODS FOR COMPUTATIONALLY INFORMED ADHESION MEASUREMENT USING THE BLISTER TEST | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | DEVITO, ALEX T | §102§103 | Non-Final OA | — | Pending | Jul 03, 2024 | |
| 18723596 | METHOD FOR CULTURING HAIR FOLLICLE-DERIVED STEM CELLS, AND USE THEREOF | Hierabio Inc. | SPENCE, JENNIFER SUZANNE | §101§102§103§112 | Non-Final OA | — | Pending | Jun 24, 2024 | |
| 18723562 | METHOD FOR CULTURING SKIN-DERIVED STEM CELLS, AND USE THEREOF | Hierabio Inc. | SPENCE, JENNIFER SUZANNE | §101§102§103§112 | Non-Final OA | — | Pending | Jun 24, 2024 | |
| 18723083 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | Suzhou Kintor Pharmaceuticals, Inc. | TOWNSLEY, SARA ELIZABETH | DP | Non-Final OA | — | Pending | Jun 21, 2024 | |
| 18665034 | RAPID SAMPLING OF INTERSTITIAL FLUID USING A MICRONEEDLE ARRAY AND VACCUM-ASSISTED SKIN PATCH | William Marsh Rice University | BERHANU, ETSUB D | 3791 | §102§103§112 | Non-Final OA | — | Pending | May 15, 2024 |
| 18660178 | METHODS FOR THE LONG-TERM EXPANSION OF GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA | WESTON, ALYSSA G | 1633 | §112Other | Non-Final OA | 46d overdue | Pending | May 09, 2024 |
| 18706958 | APPLICATION OF COMPOSITION CONTAINING EDARAVONE AND DEXBORNEOL IN IMPROVING OR TREATING COGNITIVE IMPAIRMENT | Simcere Pharmaceutical Co., Ltd. | CHAO, ALLEN | 1622 | §102§103 | Non-Final OA | — | Pending | May 02, 2024 |
| 18705061 | DRY POWDER COMPOSITIONS COMPRISING EUKARYOTIC CELLS AND METHOD OF THEIR MANUFACTURE AND USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | GEMBEH, SHIRLEY V | 1615 | §102§103 | Non-Final OA | 70d | Pending | Apr 26, 2024 |
| 18705499 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | CUREVAC SE | MIANO, JOSEPH PAUL | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18634454 | FORMATION OF STABLE SUBMICRON PEPTIDE OR PROTEIN PARTICLES BY THIN FILM FREEZING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18632697 | BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME | Musc Foundation For Research Development | COUNTS, GARY W | DP | Non-Final OA | — | Pending | Apr 11, 2024 | |
| 18691186 | NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF | Transgene SA | PUTTLITZ, KARL J | §103§112 | Non-Final OA | — | Pending | Mar 12, 2024 | |
| 18582620 | METHODS AND MEANS FOR ENHANCING RNA PRODUCTION | Curevac Manufacturing GmbH | DACE DENITO, ALEXANDRA GERALDINE | §103§112DP | Non-Final OA | — | Pending | Feb 20, 2024 | |
| 18427737 | EBOLAVIRUS AND MARBURGVIRUS VACCINES | CUREVAC SE | PARKIN, JEFFREY S | 1671 | §101§102§103 | Non-Final OA | 30d overdue | Pending | Jan 30, 2024 |
| 18293593 | CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE | CUREVAC SE | MCLEOD, AFRICA MHAIRIE | §102 | Non-Final OA | — | Pending | Jan 30, 2024 | |
| 18293455 | OSMR-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE | The Medical College of Wisconsin, Inc. | GURLEY, JAMI MICHELLE | §103§112 | Non-Final OA | — | Pending | Jan 30, 2024 | |
| 18425681 | CELL-TARGETED CYTOTOXIC CONSTRUCTS | Research Development Foundation | ROBINSON, HOPE A | 1652 | §112 | Final Rejection | — | Pending | Jan 29, 2024 |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | CUREVAC SE | BERTOGLIO, VALARIE E | 1632 | §103§112 | Final Rejection | 11d overdue | Pending | Jan 17, 2024 |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | Research Development Foundation | PAGUIO FRISING, MICHELLE F | 1651 | §103DP | Non-Final OA | 84d | Pending | Jan 16, 2024 |
| 18407624 | SMART NANOFLUIDS FOR GEOTHERMAL APPLICATIONS AND METHODS OF USE | The Board Of Regents Of The University Of Oklahoma | RUNYAN, SILVANA C | 3678 | §112 | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18572516 | COMPOSITE FILM APPLIED TO FLEXIBLE SUBSTRATE, PREPARATION METHOD THEREFOR, AND PRODUCT THEREOF | Jiangsu Favored Nanotechnology Co., Ltd. | NELSON, MICHAEL B | 1787 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18571920 | HIGH-THROUGHPUT PREPARATION OF MICROPARTICLES WITH PULSATILE RELEASE | William Marsh Rice University | TIEN, LUCY MINYU | 1612 | §103§112 | Non-Final OA | 75d | Pending | Dec 19, 2023 |
| 18545837 | EXTRACELLULAR VESICLE-ENRICHED SECRETOME COMPOSITION DERIVED FROM INDUCED PLURIPOTENT STEM CELL DERIVED-MICROGLIA AND METHODS OF USE THEREOF | Fujifilm Holdings America Corporation | BOECKELMAN, JACOB A | 1655 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18543191 | CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY | Musc Foundation For Research Development | SHUPE, ELIZABETH A | 1643 | §103 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18541241 | HUMAN ANTIBODY SPECIFICALLY BINDING TO BINDING SITE OF HEPATOCYTE RECEPTOR OF HEPATITIS B VIRUS PRES1 ANTIGEN, AND USE THEREOF | Apitbio, Inc. | BLUMEL, BENJAMIN P | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18565765 | NOVEL PRODUCTION METHOD OF FLAVOCYTOCHROME B2 | Directsens GmbH | PAK, YONG D | 1652 | §103 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18522220 | HDL MIMICKING TARGETED DRUG DELIVERY SYSTEM FOR THE TREATMENT OF SOLID TUMORS | University of North Texas Health Science Center | MOSHER, ERIC PARKER | 1612 | §103Other | Non-Final OA | 55d | Pending | Nov 28, 2023 |
| 18563234 | AMINO ACIDS BEARING A TETRAZINE MOIETY | Valanx Biotech GmbH | COPPINS, JANET L | 1628 | §112 | Non-Final OA | 84d | Pending | Nov 21, 2023 |
| 18514277 | STORAGE SOLUTIONS FOR MAINTAINING OF AXONAL VIABILITY | David M. Jackson | BOECKELMAN, JACOB A | 1655 | §101§103§112 | Non-Final OA | 49d overdue | Pending | Nov 20, 2023 |
| 18561900 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA | CORDAS, EMILY ANN | 1632 | §102§103DP | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18561889 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA | WESTON, ALYSSA G | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18290409 | COMBINED THERAPY USING ANTI-CD300C ANTIBODY | Centricsbio, Inc. | STEPHENS, AMELIA CAROLE | 1645 | §102§103§112DP | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18559460 | METHODS AND COMPOSITIONS FOR TRANSPORT, STORAGE, AND DELIVERY OF ADENO-ASSOCIATED VIRAL VECTOR AND OTHER MOLECULES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KNIGHT, TERESA E | 1634 | §103 | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18558811 | PHARMACEUTICAL COMPOSITION COMPRISING CHORION EXTRACT-DERIVED EXOSOMES AS ACTIVE INGREDIENT FOR PROMOTING OSTEOGENESIS | Korea University Research And Business Foundation | WESTON, ALYSSA G | 1633 | §102§103 | Final Rejection | — | Pending | Nov 03, 2023 |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | William Marsh Rice University | SALMON, KATHERINE D | 1682 | §101§102 | Final Rejection | 28d overdue | Pending | Oct 27, 2023 |
| 18556648 | ANTIBODY COCKTAIL FOR TREATMENT OF EBOLAVIRUS INFECTIONS | VANDERBILT UNIVERSITY | LU, CHENG | 1642 | §102§103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18490131 | ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT | The Board Of Regents Of The University Of Texas System | CHONG, KIMBERLY | §103§112DP | Non-Final OA | — | Pending | Oct 19, 2023 | |
| 18553893 | ANTIMICROBIAL ELUTING AIRWAY DEVICES | The Children's Hospital of Philadelphia | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | — | Pending | Oct 04, 2023 |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | Musc Foundation For Research Development | SZNAIDMAN, MARCOS L | 1628 | §102§103 | Non-Final OA | 10d overdue | Pending | Sep 29, 2023 |
| 18471280 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA | The Board Of Regents Of The University Of Texas System | CHONG, KIMBERLY | 1636 | §103§112 | Non-Final OA | — | Pending | Sep 20, 2023 |
| 18470317 | COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL DISEASES | Research Foundation Of The City University Of New York | HUI, SAN MING R | 1627 | §103§112 | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18549844 | GENERATION OF HUMAN PEANUT ALLERGEN-SPECIFIC IGE MONOCLONAL ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE | VANDERBILT UNIVERSITY | SANG, HONG | 1646 | §112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18549645 | DRY POWDER FORMULATIONS OF NUCLEIC ACID LIPID NANOPARTICLES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SHOMER, ISAAC | 1612 | §102§103 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SALMON, KATHERINE D | 1682 | §103 | Final Rejection | 161d overdue | Pending | Sep 07, 2023 |
| 18548413 | COLLAGENOUS EXTRACTS FOR USE AS A MEDICAMENT | Jellagen Ltd. | KATAKAM, SUDHAKAR | 1658 | §102§103§112 | Non-Final OA | 24d overdue | Pending | Aug 30, 2023 |
| 18547687 | METHODS FOR POLYPEPTIDE PROCESSING AND ANALYSIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | XU, XIAOYUN | 1797 | §101§102§103 | Non-Final OA | 17d overdue | Pending | Aug 23, 2023 |
| 18449100 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM SMALL VOLUMES OF PERIPHERAL BLOOD | Fujifilm Cellular Dynamics, Inc. | GRABER, JAMES J | 1631 | §103§112Other | Non-Final OA | 27d | Pending | Aug 14, 2023 |
| 18546141 | LOW INTENSITY ULTRASOUND COMBINATION CANCER THERAPIES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MACFARLANE, STACEY NEE | 1675 | §103§112 | Non-Final OA | 26d | Pending | Aug 11, 2023 |
| 18264774 | COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH HYALURONAN OVERPRODUCTION | The Royal Veterinary College | GAUGER, PAUL RANDALL | 1629 | §112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18264457 | LITHIATED METAL ORGANIC FRAMEWORKS WITH A BOUND SOLVENT FOR SECONDARY BATTERY APPLICATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LI, AIQUN | 1766 | §102 | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18365991 | Weight Loss Regimen | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ANGELL, JON E | 1637 | §103§112Other | Non-Final OA | 54d | Pending | Aug 05, 2023 |
| 18264413 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | The Board Of Regents Of The University Of Texas System | O DELL, DAVID K | 1621 | §112 | Non-Final OA | 53d | Pending | Aug 04, 2023 |
| 18365712 | PROCESS OF MANUFACTURE OF ANNEXIN V | Annexin Pharmaceuticals AB | IANNUZO, NATALIE NMN | 1653 | §103§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18264143 | COMPOSITIONS AND METHODS FOR TREATMENT OF HIDRADENITIS SUPPURATIVA | Suzhou Kintor Pharmaceuticals, Inc. | HUI, SAN MING R | 1627 | §103 | Non-Final OA | 15d | Pending | Aug 03, 2023 |
| 18275529 | MONOCLONAL ANTIBODY FOR SPECIFICALLY RECOGNIZING GLYPICAN-3, AND APPLICATION THEREOF | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | HADDAD, MAHER M | 1641 | §102§112 | Non-Final OA | — | Pending | Aug 02, 2023 |
| 18261983 | BONE-SPECIFIC DELIVERY OF POLYPEPTIDES | BAYLOR COLLEGE OF MEDICINE | DUNN, LINDSAY MICHELLE | 1644 | §102§103§112 | Non-Final OA | 17d overdue | Pending | Jul 18, 2023 |
| 18271991 | APPLICATION OF CILOSTAZOL-CONTAINING COMPOSITION IN PREPARING DRUG FOR TREATING CEREBROVASCULAR DISEASE | Neurodawn Pharmaceutical Co., Ltd. | SCHMITT, MICHAEL J | 1629 | §103 | Non-Final OA | 71d | Pending | Jul 12, 2023 |
| 18270476 | ORAL SOLID FORMULATION FOR COLON CLEANSING | Taejoon Pharmaceutical Co., Ltd. | ATKINSON, JOSHUA ALEXANDER | 1612 | DP | Non-Final OA | 8d overdue | Pending | Jun 29, 2023 |
| 18270028 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai Kunheng Pharma-Tech Co., Ltd. | HEITMEIER, KENDALL NICOLE | 1621 | §102§103Other | Final Rejection | 26d | Pending | Jun 28, 2023 |
| 18267518 | CD5 ANTIBODY AND USE THEREOF | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | XIAO, YAN | 1642 | §112 | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | Research Development Foundation | BUTTICE, AUDREY L | 1647 | §103§112 | Non-Final OA | 28d overdue | Pending | Jun 09, 2023 |
| 18332603 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC | MOU, LIYUAN | 1628 | §102§103§112Other | Non-Final OA | 157d overdue | Pending | Jun 09, 2023 |
| 18256897 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | COHEN, MICHAEL P | 1612 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18265780 | EXHAUST GAS FILTERING APPARATUS AND COATING EQUIPMENT | Jiangsu Favored Nanotechnology Co., Ltd. | YUAN, DAH WEI D | 1717 | §102§103 | Final Rejection | 8d overdue | Pending | Jun 07, 2023 |
| 18255745 | METHODS FOR IDENTIFYING LILRB-BLOCKING ANTIBODIES | The Board Of Regents Of The University Of Texas System | HALVORSON, MARK | 1646 | §112 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18324828 | L-DNA ENCRYPTED TRACERS | VANDERBILT UNIVERSITY | CASH, KAILEY ELIZABETH | 1683 | §103§112 | Final Rejection | — | Pending | May 26, 2023 |
| 18254595 | DEVICE FOR PREPARING A DNA PRODUCT BY MEANS OF CAPILLARY POLYMERASE CHAIN REACTION | Tesla Automation GmbH | CROW, ROBERT THOMAS | 1683 | §102§103§112 | Non-Final OA | — | Pending | May 25, 2023 |
| 18254261 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics | PECKHAM, RICHARD GRANT | 1627 | §102§103 | Non-Final OA | 33d | Pending | May 24, 2023 |
| 18038181 | DIRECT LYSIS APPARATUS AND METHODS FOR MOLECULAR DIAGNOSTICS | Nuclein, LLC | NGUYEN, HENRY H | 1758 | §102§103 | Non-Final OA | 82d | Pending | May 22, 2023 |
| 18320598 | RNA SEQUENCE ADAPTATION | CUREVAC SE | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112DPOther | Non-Final OA | 62d | Pending | May 19, 2023 |
| 18253755 | USE OF MICROVIRIN IN THE IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS MANNOSE-CAPPED LIPOARABINOMANNAN | UNIVERSITY OF CAPE TOWN | DEVI, SARVAMANGALA | 1645 | §103§112 | Non-Final OA | 14d | Pending | May 19, 2023 |
| 18037598 | SIRNA FOR TREATING HEPATIC FIBROSIS AND DELIVERY PREPARATION THEREOF | Youjia (Hangzhou) Biomedical Technology Co., Ltd. | SHEN, WU CHENG WINSTON | 1682 | §103 | Non-Final OA | — | Pending | May 18, 2023 |
| 18037282 | APPARATUS AND METHODS FOR MOLECULAR DIAGNOSTICS | Nuclein, LLC | KRCHA, MATTHEW D | 1796 | §103§112 | Final Rejection | — | Pending | May 16, 2023 |
| 18315781 | METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS | CUREVAC SE | ARIETI, RUTH SOPHIA | 1635 | §103§112DP | Non-Final OA | — | Pending | May 11, 2023 |
| 18036488 | SALICYLIC ACID-INDUCIBLE GENE EXPRESSION COMPOSITIONS AND SYSTEMS FOR CELLS | UNIVERSITY OF HOUSTON SYSTEM | LEONARD, ARTHUR S | 1631 | §102§103§112 | Non-Final OA | 27d | Pending | May 11, 2023 |
| 18252185 | METHOD FOR PREDICTING RESPONSIVENESS TO PLK1 INHIBITION | National University Of Singapore | BAUSCH, SARAE L | 1699 | §101§102 | Non-Final OA | 28d | Pending | May 08, 2023 |
| 18250532 | DIRECTIONAL AND SCALABLE ELECTRODE ARRAY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | PORTER, JR, GARY A | 3796 | §102§103 | Final Rejection | 16d overdue | Pending | Apr 25, 2023 |
| 18033464 | ANTIBODIES FOR USE IN THE DETECTION AND TREATMENT OF HEART DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MERTZ, PREMA MARIA | 1674 | §112 | Non-Final OA | — | Pending | Apr 24, 2023 |
| 18028650 | INJECTABLE CALCIUM PHOSPHATE-BASED BONE GRAFT COMPOSITION HAVING HIGH ELASTICITY AND PREPARATION METHOD THEREOF | Cg Bio Co., Ltd. | ZHANG SPIERING, DONGXIU | 1616 | §103 | Non-Final OA | — | Pending | Mar 27, 2023 |
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | CUREVAC SE | SHIN, DANA H | 1635 | DP | Final Rejection | 58d overdue | Pending | Mar 13, 2023 |
| 18120191 | PROGRAMMED CELLS FOR TARGETED ARTICULAR CARTILAGE AND BONE REGENERATION | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | BUTTICE, AUDREY L | 1644 | §102§103§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18044909 | RECOMBINANT PROTEINS WITH INCREASED SOLUBILITY AND STABILITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18044877 | PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE AND A PROTEIN | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | 16d overdue | Pending | Mar 10, 2023 |
| 18044668 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | STEELE, AMBER D | 1658 | §112 | Final Rejection | 15d overdue | Pending | Mar 09, 2023 |
| 18178368 | DIRECT METHOD OF SYNTHESIS OF ZNO NWS/SWCNTS AND ZNO NWS/GRAPHENE HETEROSTRUCTURES | Saint Louis University | WALTERS JR, ROBERT S | 1717 | §103 | Non-Final OA | 19d | Pending | Mar 03, 2023 |
| 18043976 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | Cyprumed GmbH | WISTNER, SARAH CLINKSCALES | 1616 | §103§112DP | Final Rejection | — | Pending | Mar 03, 2023 |
| 18023136 | MODIFIED POLYPEPTIDES WITH IMPROVED PROPERTIES | The University of Queensland | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§103§112 | Non-Final OA | — | Pending | Feb 24, 2023 |
| 18173246 | ELECTROTHERMAL FLOW-ENHANCED ELECTROCHEMICAL MAGNETO-IMMUNOSENSOR | William Marsh Rice University | EVANS, CHRISTOPHER RYAN | 1677 | §103 | Final Rejection | — | Pending | Feb 23, 2023 |
| 18041811 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | UNIVERSITY OF CONNECTICUT | RONEY, CELESTE A | 1612 | §103 | Non-Final OA | 16d | Pending | Feb 16, 2023 |
| 18041475 | METHOD OF PRODUCING PHARMACEUTICAL COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BAUER, NICOLA MARIA | 1621 | §102§103§112 | Non-Final OA | — | Pending | Feb 13, 2023 |
| 18041479 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ATKINSON, JOSHUA ALEXANDER | 1612 | DPOther | Final Rejection | — | Pending | Feb 13, 2023 |
| 18018866 | TOTAL SYNTHESES OF SPECIALIZED PRO-RESOLVING MEDIATORS (SPMS), STRUCTURAL ISOMERS AND STRUCTURAL ANALOGS | UNIVERSITE LAVAL | CRAIG, KAILA ANGELIQUE | 1618 | §103§112 | Non-Final OA | 70d | Pending | Jan 30, 2023 |
| 18160926 | HEPATITIS C VIRUS MODIFIED E2 GLYCOPROTEIN AND USES THEREOF AS VACCINES | Saint Louis University | HILL, MYRON G | 1671 | §112 | Non-Final OA | — | Pending | Jan 27, 2023 |
| 18017669 | USE OF PERLECAN AND FRAGMENTS THEREOF TO REDUCE THE RISK OF DEATH IN STROKE PATIENTS | Stream Biomedical, Inc. | STEELE, AMBER D | 1658 | §102§112 | Non-Final OA | 28d overdue | Pending | Jan 23, 2023 |
| 18016275 | ANTIBODY DRUG CONJUGATE INTERMEDIATE CONTAINING SN38 AND ITS PREPARATION METHOD | Mabplex International Co., Ltd. | SKOKO III, JOHN JOSEPH | 1643 | §103§112 | Non-Final OA | 83d | Pending | Jan 13, 2023 |
| 18005562 | ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD) | Xyone Therapeutics, Inc. | QIAN, CELINE X | 1637 | §102§112 | Final Rejection | 51d overdue | Pending | Jan 13, 2023 |
| 18014746 | SUPER HYDROPHOBIC FILM LAYER, PREPARATION METHOD THEREOF,AND PRODUCT THEREOF | Jiangsu Favored Nanotechnology Co., Ltd. | EMPIE, NATHAN H | 1712 | §103§112 | Non-Final OA | 6d | Pending | Jan 06, 2023 |
| 18001425 | MOLECULAR MARKERS AND METHODS FOR SAMPLE ANALYSIS VIA MASS SPECTROMETRY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | TURPIN, ZACHARY MARK | 1682 | §103§112 | Final Rejection | — | Pending | Dec 09, 2022 |
| 18062918 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS | Luminex Corporation | GRAY, JESSICA | 1682 | §112DP | Final Rejection | — | Pending | Dec 07, 2022 |
| 18008134 | MODEL FOR PREDICTION OF TOLERABILITY ISSUES IN CONNECTION WITH INTRAVENOUS ADMINISTRATION OF THERAPEUTIC ANTIBODIES | Bioinvent International AB | HALVORSON, MARK | 1646 | §101§103§112 | Non-Final OA | 63d | Pending | Dec 02, 2022 |
| 18056970 | METHODS, SYSTEMS AND KITS FOR POLYPEPTIDE PROCESSING AND ANALYSIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BOESEN, CHRISTIAN C | 1684 | §102 | Non-Final OA | — | Pending | Nov 18, 2022 |
| 18055822 | METHODS AND COMPOSITIONS FOR DETERMINING, AND FOR MINIMIZING, THE LIKELIHOOD OF DEVELOPMENT OF ALLERGY IN INFANTS | Murdoch Children'S Research Institute | WILDER, CYNTHIA B | 1681 | §101§102 | Non-Final OA | — | Pending | Nov 15, 2022 |
| 17998291 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | — | Pending | Nov 09, 2022 |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | Research Development Foundation | LI, RUIXIANG | 1674 | §112 | Non-Final OA | 77d overdue | Pending | Nov 03, 2022 |
| 17997696 | QUANTITATIVE BLOCKER DISPLACEMENT AMPLIFICATION (QBDA) SEQUENCING FOR CALIBRATION-FREE AND MULTIPLEXED VARIANT ALLELE FREQUENCY QUANTITATION | William Marsh Rice University | PRIEST, AARON A | 1681 | §103DP | Final Rejection | 43d overdue | Pending | Nov 01, 2022 |
| 18050687 | USE OF FATE MODULATORS TO IMPROVE NERVE REGENERATION | The Board Of Regents Of The University Of Texas System | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | — | Pending | Oct 28, 2022 |
| 17996618 | LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 14d | Pending | Oct 19, 2022 |
| 17995865 | APPARATUS AND METHODS FOR ACQUISITION OF MICROBIOPSY TISSUE SAMPLES USING A LASER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | CERIONI, DANIEL LEE | 3791 | §103§112 | Non-Final OA | — | Pending | Oct 10, 2022 |
| 17938003 | KRATOM OPIOID DERIVATIVES FOR THE TREATMENT OF ALCOHOL USE DISORDER | The Trustees of Columbia University in the City of New York | MOORE, SUSANNA | 1624 | §103 | Non-Final OA | 28d | Pending | Oct 04, 2022 |
| 17916998 | DECELLULARIZED MENISCAL CARTILAGE AND USES THEROF | The Children's Hospital of Philadelphia | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Final Rejection | 111d overdue | Pending | Oct 04, 2022 |
| 17907386 | FOOD COLOURING AGENTS | V2Food Pdy Ltd. | DIVIESTI, KARLA ISOBEL | 1792 | §103§112 | Non-Final OA | 23d | Pending | Sep 26, 2022 |
| 17906913 | CELL ACTIVATABLE IRON CHELATORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | DICKINSON, PAUL W | 1618 | §102§112 | Non-Final OA | — | Pending | Sep 21, 2022 |
| 17931669 | METHODS FOR THE PRODUCTION OF COMMITTED CARDIAC PROGENITOR CELLS | Fujifilm Cellular Dynamics, Inc. | GONZALES, JOSEPHINE MARIA | 1631 | §102§103 | Final Rejection | 62d | Pending | Sep 13, 2022 |
| 17931440 | COMPOSITIONS OF INDUCED PLURIPOTENT STEM CELL-DERIVED CELLS AND METHODS OF USE THEREOF | Fujifilm Cellular Dynamics, Inc. | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17641048 | METHOD FOR SEQUENCING RNA OLIGONUCLEOTIDES | Cemm - Forschungszentrum Für Molekulare Medizin GmbH | CASH, KAILEY ELIZABETH | 1683 | §103§112 | Final Rejection | — | Pending | Sep 08, 2022 |
| 17905143 | TREATMENT OF CARM1-OVEREXPRESSING AND/OR ARID1A MUTANT CANCERS WITH IRE-1/XBP-1 INHIBITORS | The Wistar Institute | SIMMONS, CHRIS E | 1622 | §103§112 | Non-Final OA | — | Pending | Aug 26, 2022 |
| 17822332 | TARGETED MEASURE OF TRANSCRIPTIONAL ACTIVITY RELATED TO HORMONE RECEPTORS | Yale University | JOHANNSEN, DIANA B | 1682 | §103§112 | Final Rejection | — | Pending | Aug 25, 2022 |
| 17821931 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ENGLISH, CONNOR KENNEDY | 1625 | §103 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17820559 | METHOD FOR IN VITRO TRANSCRIPTION USING AN IMMOBILIZED RESTRICTION ENZYME | Curevac AG | POHNERT, STEVEN C | 1683 | §103§112 | Final Rejection | — | Pending | Aug 17, 2022 |
| 17820277 | DIGITAL AMPLIFICATION ASSAY ANALYSIS METHOD | Luminex Corporation | KIM, YOUNG J | 1681 | Other | Final Rejection | 8d overdue | Pending | Aug 17, 2022 |
| 17904473 | CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTAU) AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | HAM, JIEUN | 1643 | §103§112 | Non-Final OA | — | Pending | Aug 17, 2022 |
| 17819234 | NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY | Cancer Research Technology Limited | OUSPENSKI, ILIA I | 1644 | §102§112DPOther | Non-Final OA | 77d | Pending | Aug 11, 2022 |
| 17819268 | DRY LIPOSOME FORMULATIONS AND RELATED METHODS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | HOERNER, PAUL ELLSWORTH | 1611 | §103Other | Non-Final OA | 4d overdue | Pending | Aug 11, 2022 |
| 17798851 | COMPOSITIONS AND METHODS FOR INDUCIBLE ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION | The Children's Hospital of Philadelphia | SINGH, ANOOP KUMAR | 1632 | §102§103§112Other | Final Rejection | — | Pending | Aug 10, 2022 |
| 17759817 | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103DPOther | Non-Final OA | — | Pending | Jul 29, 2022 |
| 17815711 | GENOME ENGINEERING THE HUMAN IMMUNOGLOBULIN LOCUS TO EXPRESS RECOMBINANT BINDING DOMAIN MOLECULES | UNIVERSITY OF SOUTHERN CALIFORNIA | KONOPKA, CATHERINE ANNE | 1635 | §102§103§112 | Non-Final OA | 31d overdue | Pending | Jul 28, 2022 |
| 17759542 | NUTRACEUTICAL EXTRACTS OF HIPPOPHAE RHAMNOIDES AND TERMINALIA CHEBULA AND USES THEREOF | Biomics, LLC | CAIN, JENNIFER LYNN | 1655 | §103 | Non-Final OA | — | Pending | Jul 27, 2022 |
| 17794920 | COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES | UNIVERSITY OF SOUTHERN CALIFORNIA | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | 72d | Pending | Jul 22, 2022 |
| 17814198 | T CELLS EXPRESSING MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LIU, SUE XU | 1616 | §102§103DP | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17808180 | METHODS AND COMPOSITIONS FOR DISCRETE MELT ANALYSIS | Luminex Corporation | SISSON, BRADLEY L | 1682 | §103§112Other | Final Rejection | 56d | Pending | Jun 22, 2022 |
| 17787061 | PEPTIDE | UNIVERSITY OF SOUTHAMPTON | ZAHORIK, AMANDA MARY | 1636 | §112 | Non-Final OA | — | Pending | Jun 17, 2022 |
| 17782169 | COATING EQUIPMENT | Jiangsu Favored Nanotechnology Co., Ltd. | FORD, NATHAN K | 1716 | §103 | Final Rejection | — | Pending | Jun 03, 2022 |
| 17782314 | A BIOMARKER AND USES THEREFOR | Perron Institute For Neurological And Translational Science Limited | KAPUSHOC, STEPHEN THOMAS | 1683 | §101§112 | Non-Final OA | 32d overdue | Pending | Jun 03, 2022 |
| 17782147 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JONES, DAMERON LEVEST | 1618 | §103§112 | Non-Final OA | 39d | Pending | Jun 02, 2022 |
| 17746569 | ANTI-CD300C MONOCLONAL ANTIBODY AND BIOMARKER THEREOF FOR PREVENTING OR TREATING CANCER | Centricsbio, Inc. | BERHANE, SELAM | 1675 | §112 | Non-Final OA | — | Pending | May 17, 2022 |
| 17777102 | INCLUSION COMPLEXES OF PHARMACEUTICALS AND CYCLIC OLIGOMERS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MEYERS, ELIZABETH ANNE | 1617 | §103§112 | Final Rejection | 55d | Pending | May 16, 2022 |
| 17774838 | METHODS FOR THE TREATMENT OF DYSMYELINATING/DEMYELINATING DISEASES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | NEAGU, IRINA | 1629 | §103 | Final Rejection | — | Pending | May 05, 2022 |
| 17716389 | INTERFACIAL SEEDING OF CELLS AND PARTICLES ON SURFACES FOR DIAGNOSTICS AND THERAPEUTICS | William Marsh Rice University | SCHUBERG, LAURA J | 1631 | §103 | Non-Final OA | — | Pending | Apr 08, 2022 |
| 17698906 | COMPOSITIONS FOR DELIVERY OF DRUG COMBINATIONS TO TREAT LUNG DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | 28d overdue | Pending | Mar 18, 2022 |
| 17589879 | METHOD FOR PRODUCING RNA | Curevac Real Estate GmbH | YU, TIAN NMN | 1681 | §103 | Non-Final OA | — | Pending | Jan 31, 2022 |
| 17631433 | ANTIBODIES TO CANDIDA AND USES THEREOF | Stadius Biopharma, LLC | MIDDLETON, DANAYA L | 1674 | §112 | Final Rejection | — | Pending | Jan 28, 2022 |
| 17576583 | ARTIFICIAL NUCLEIC ACID MOLECULES | Curevac AG | LEITH, NANCY J | 1636 | §101§103§112Other | Non-Final OA | 30d | Pending | Jan 14, 2022 |
| 17567868 | METHODS FOR PREDICTING KINASE INHIBITOR RESISTANCE | Research Development Foundation | DESAI, ANAND U | 1655 | §103§112 | Final Rejection | 24d overdue | Pending | Jan 03, 2022 |
| 17597149 | IMPROVED FIX FUSION PROTEIN AND CONJUGATE AND USE THEREOF | Jiangsu Gensciences Inc. | SZPERKA, MICHAEL EDWARD | 1641 | §112 | Final Rejection | — | Pending | Dec 28, 2021 |
| 17620605 | METHODS FOR DUPLEX SEQUENCING OF CELL-FREE DNA AND APPLICATIONS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | PARISI, JESSICA DANIELLE | 1684 | §103 | Final Rejection | — | Pending | Dec 17, 2021 |
| 17554861 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION | LEONARD, ARTHUR S | 1631 | §103 | Final Rejection | — | Pending | Dec 17, 2021 |
| 17620047 | ROTAVIRUS MRNA VACCINE | Curevac AG | GRABER, JAMES J | 1631 | §102§103§112Other | Final Rejection | 8d overdue | Pending | Dec 16, 2021 |
| 17596622 | USE OF SRRD IN THE INHIBITION OF PROTEIN AGGREGATION | The Children's Hospital of Philadelphia | WANG, CHANG YU | 1675 | §112 | Final Rejection | 28d overdue | Pending | Dec 14, 2021 |
| 17548467 | SYSTEMS AND METHODS FOR LASER-INDUCED CALCIUM FRACTURES | Research Development Foundation | ANJARIA, SHREYA PARAG | 3796 | §103 | Non-Final OA | 134d overdue | Pending | Dec 10, 2021 |
| 17613292 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | AGGARWAL, SAHIL CHANDER | 1623 | §103§112DP | Non-Final OA | — | Pending | Nov 22, 2021 |
| 17611315 | METHODS AND APPARATUS FOR HIGH-SPEED AND HIGH-ASPECT RATIO LASER SUBTRACTIVE MATERIAL PROCESSING | Research Development Foundation | FEDORKY, MEGAN TAYLOR | 3796 | §103§112 | Non-Final OA | — | Pending | Nov 15, 2021 |
| 17607837 | MICRO-RNA SITE BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS | The Trustees of the University of Pennsylvania | SULLIVAN, STEPHANIE LAUREN | 1635 | §102§103§112 | Final Rejection | 6d | Pending | Oct 29, 2021 |
| 17594651 | CRISPR/CAS9 GENE EDITING OF ATXN2 FOR THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 2 | The Children's Hospital of Philadelphia | BABIC, CHRISTOPHER M | 1633 | §103 | Non-Final OA | 8d overdue | Pending | Oct 25, 2021 |
| 17485846 | METHODS AND APPARATUS FOR CONDITIONING CELL POPULATIONS FOR CELL THERAPIES | The Board Of Regents Of The University Of Texas System | BATES, KEENAN ALEXANDER | 1631 | §103 | Final Rejection | — | Pending | Sep 27, 2021 |
| 17598780 | NUCLEAR-DERIVED EXOSOMES AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SKOKO III, JOHN JOSEPH | 1643 | §101§103§112 | Final Rejection | 27d | Pending | Sep 27, 2021 |
| 17441869 | SURFACE-MODIFIED DOPED TITANIUM DIOXIDE NANOPARTICLES AND USES | The Board Of Regents Of The University Of Oklahoma | PROSSER, ALISSA J | 1619 | §103§112Other | Final Rejection | — | Pending | Sep 22, 2021 |
| 17378954 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) | Curevac AG | WILSON, MICHAEL C | 1638 | §103 | Non-Final OA | 81d overdue | Pending | Jul 19, 2021 |
| 17416227 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | DENT, ALANA HARRIS | 1643 | §102§103 | Final Rejection | — | Pending | Jun 18, 2021 |
| 17289877 | T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE | The Children's Hospital of Philadelphia | REDDIG, PETER J | 1646 | §103 | Non-Final OA | 30d overdue | Pending | Apr 29, 2021 |
| 17276032 | COMBINATION CANCER THERAPIES | The Board Of Regents Of The University Of Oklahoma | ELENISTE, PIERRE PAUL | 1622 | §103§112 | Non-Final OA | 74d overdue | Pending | Mar 12, 2021 |
| 17193511 | TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | GODDARD, LAURA B | 1642 | DP | Final Rejection | — | Pending | Mar 05, 2021 |
| 17265302 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS | The Children's Hospital of Philadelphia | MCLEOD, AFRICA MHAIRIE | 1635 | §103DP | Non-Final OA | 8d overdue | Pending | Feb 02, 2021 |
| 17146912 | METHOD FOR REDUCING THE OCCURRENCE OF THROMBOSIS OR THROMBOEMBOLISM | Grifols Shared Services North America, Inc. | BEANE, RANDALL L | 1654 | §102§103§112 | Final Rejection | 28d | Pending | Jan 12, 2021 |
| 16972259 | DETECTION OF IMMUNE CHECKPOINT MOLECULES BY DEGLYCOSYLATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | RAMADAN, OMAR | 1678 | §103§112 | Non-Final OA | 19d overdue | Pending | Dec 04, 2020 |
| 17054312 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | William Marsh Rice University | VAN DRUFF, SYDNEY | 1643 | §103 | Non-Final OA | 12d | Pending | Nov 10, 2020 |
| 17045535 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH | MIKNIS, ZACHARY J | 1658 | §103§112 | Final Rejection | 9d | Pending | Oct 06, 2020 |
| 16975058 | FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES | Mucpharm Pty Ltd. | FERNANDEZ, SUSAN EMILY | 1651 | §103§112Other | Final Rejection | — | Pending | Aug 21, 2020 |
| 16933773 | NUCLEIC ACID PURIFICATION | ZYMO RESEARCH CORPORATION | NGUYEN, QUANG | 1631 | §103 | Final Rejection | 100d overdue | Pending | Jul 20, 2020 |
| 16860004 | MULTIVASCULAR NETWORKS AND FUNCTIONAL INTRAVASCULAR TOPOLOGIES WITHIN BIOCOMPATIBLE HYDROGELS | William Marsh Rice University | PELLEGRINO, BRIAN E | 3799 | §103§112 | Final Rejection | — | Pending | Apr 27, 2020 |
| 16757297 | METHODS AND COMPOSITIONS FOR THE PURIFICATION OF UNBIASED RNA | ZYMO RESEARCH CORPORATION | GREENE, CAROLYN LEE | 1681 | §103 | Final Rejection | 9d | Pending | Apr 17, 2020 |
| 16348115 | AUTOMATED METHOD FOR RELEASE OF NUCLEIC ACIDS FROM MICROBIAL SAMPLES | ZYMO RESEARCH CORPORATION | MISHRA, DEEPA | 1657 | §103 | Non-Final OA | 7d | Pending | May 07, 2019 |
| 16098145 | IMPROVED DRUG FORMULATIONS | AustinPx, LLC | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | 98d overdue | Pending | Nov 01, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial